Fenofibrate Combined With Ursodeoxycholic Acid ( DrugBank: Fenofibrate, Ursodeoxycholic acid )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 93 | Primary biliary cholangitis | 3 |
93. Primary biliary cholangitis
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05751967 (ClinicalTrials.gov) | February 22, 2023 | 13/12/2022 | Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis | A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis and an Inadequate Response to Ursodeoxycholic Acid | Primary Biliary Cholangitis | Drug: Placebo Combined With Ursodeoxycholic Acid;Drug: Fenofibrate Combined With Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | NULL | Recruiting | 18 Years | 75 Years | All | 150 | Phase 3 | China |
| 2 | NCT05749822 (ClinicalTrials.gov) | February 17, 2023 | 29/12/2022 | Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis | Fenofibrate Combined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliary Cholangitis Who Had an Inadequate Response to Ursodeoxycholic Acid | Primary Biliary Cholangitis | Drug: Fenofibrate 200mg;Drug: Placebo;Drug: UDCA | Xijing Hospital of Digestive Diseases | NULL | Recruiting | 18 Years | 75 Years | All | 104 | Phase 2/Phase 3 | China |
| 3 | NCT02965911 (ClinicalTrials.gov) | January 2016 | 15/11/2016 | Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA | A Randomized Controlled Clinical Trial on the Efficacy and Safety of Fenofibrate Combined With Ursodeoxycholic Acid in PBC Patients With an Incomplete Biochemical Response to UDCA | Primary Biliary Cirrhosis | Drug: Fenofibrate;Drug: UDCA | Beijing 302 Hospital | NULL | Withdrawn | 18 Years | 65 Years | All | 0 | Phase 1/Phase 2 | China |